SCHEMBL4380469

SCHEMBL4380469

C=CCN1CCN(C(=O)Cc2sc3ccc(Cl)cc3c2C)CC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.50
RAB9A P51151 4/20 0.40
NPC1 O15118 3/20 0.40
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LMNA P02545 4/20 0.36
GAA P10253 2/20 0.36
USP2 O75604 1/20 0.36
ATM Q13315 1/20 0.36
HTR6 P50406 1/20 0.36
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALDH1A1 P00352 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14218140 0.87 MAPT (0.54) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL4380711 0.79 MAPT (0.50) MAPTL3MBTL1HTR6ALDH1A1
SCHEMBL4380482 0.78 MAPT (0.49) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL2834155 0.77 MAPT (0.50) MAPTL3MBTL1HTR6NPSR1
SCHEMBL14435191 0.73 MAPT (0.56) MAPTMEN1KMT2AL3MBTL1GAA
Tianafac SCHEMBL2109723 0.73 MAPT (0.67) MAPTMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL107073 0.72 ENPP2 (0.55) MAPTKMT2ALMNAHTTALDH1A1
Hydrochloric Acid SCHEMBL9050783 0.70 MAPT (0.49) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL3148840 0.67 HTR6 (0.53) MAPTKMT2AHTR6HTT
SCHEMBL4376257 0.67 CYP1A2 (0.72) MAPTRAB9ANPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP claimed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 MAPT 1441/4885RAB9A 3209/4885NPC1 1743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.